These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 38383371)
1. RNA-binding proteins signature is a favorable biomarker of prognosis, immunotherapy and chemotherapy response for cervical cancer. Chen X; Dong X; Li H; Wu T; Liu H; Wu J; Ge W; Hao L; Zhang Z Cancer Cell Int; 2024 Feb; 24(1):80. PubMed ID: 38383371 [TBL] [Abstract][Full Text] [Related]
2. Identification and Validation of the Anoikis-Related Gene Signature as a Novel Prognostic Model for Cervical Squamous Cell Carcinoma, Endocervical Adenocarcinoma, and Revelation Immune Infiltration. Jin QQ; Mei J; Hong L; Wang R; Wu SY; Wang SL; Jiang XY; Yang YT; Yao H; Zhang WY; Zhu YT; Ying J; Tian L; Chen G; Zhou SG Medicina (Kaunas); 2023 Feb; 59(2):. PubMed ID: 36837559 [No Abstract] [Full Text] [Related]
3. Identification of immune related molecular subtypes and prognosis model for predicting prognosis, drug resistance in cervical squamous cell carcinoma. Hu D; Zhang Z; Zhang Y; Huang K; Li X Front Genet; 2023; 14():1137995. PubMed ID: 37007965 [No Abstract] [Full Text] [Related]
4. Identification and validation of a novel necroptosis-related prognostic signature in cervical squamous cell carcinoma and endocervical adenocarcinoma. Zhang W; Cao W; Tong Z; Jin Q; Jiang X; Yang Y; Yao H; Chen G; Gao W; Zhu Y; Zhou S Front Oncol; 2022; 12():1011000. PubMed ID: 36185274 [TBL] [Abstract][Full Text] [Related]
5. A prognostic signature based on immune-related genes for cervical squamous cell carcinoma and endocervical adenocarcinoma. Liu J; Wu Z; Wang Y; Nie S; Sun R; Yang J; Cheng W Int Immunopharmacol; 2020 Nov; 88():106884. PubMed ID: 32795900 [TBL] [Abstract][Full Text] [Related]
6. Exploration of a Robust and Prognostic Immune Related Gene Signature for Cervical Squamous Cell Carcinoma. Zuo Z; Xiong J; Zeng C; Jiang Y; Xiong K; Tao H; Guo Y Front Mol Biosci; 2021; 8():625470. PubMed ID: 33748188 [No Abstract] [Full Text] [Related]
7. Development and validation of a prognostic prediction model for cervical cancer patients treated with radical radiotherapy: a study based on TCGA database. He JY; Li ZM; Chen YT; Zhao BH; Yu C Transl Cancer Res; 2024 Apr; 13(4):1721-1736. PubMed ID: 38737688 [TBL] [Abstract][Full Text] [Related]
8. Identification of prognostic biomarkers for cervical cancer based on programmed cell death-related genes and assessment of their immune profile and response to drug therapy. Feng S; Wang Z; Zhang H; Hou B; Xu Y; Hao S; Lu Y J Gene Med; 2024 Jan; 26(1):e3643. PubMed ID: 38044747 [TBL] [Abstract][Full Text] [Related]
9. Angiogenesis-related lncRNAs index: A predictor for CESC prognosis, immunotherapy efficacy, and chemosensitivity. Huang X; Yi G; Xu J; Gou S; Chen H; Chen X; Quan X; Xie L; Teichmann AT; Yang G; Chi H; Wang Q J Cancer; 2024; 15(10):3095-3113. PubMed ID: 38706901 [TBL] [Abstract][Full Text] [Related]
10. Identification of a necroptosis-related prognostic gene signature associated with tumor immune microenvironment in cervical carcinoma and experimental verification. Sun K; Huang C; Li JZ; Luo ZX World J Surg Oncol; 2022 Oct; 20(1):342. PubMed ID: 36253777 [TBL] [Abstract][Full Text] [Related]
11. Gene signatures, immune infiltration, and drug sensitivity based on a comprehensive analysis of m6a RNA methylation regulators in cervical cancer. Lu X; Li R; Ying Y; Zhang W; Wang W J Transl Med; 2022 Sep; 20(1):385. PubMed ID: 36058934 [TBL] [Abstract][Full Text] [Related]
12. A Novel Prognostic Risk Model for Cervical Cancer Based on Immune Checkpoint HLA-G-Driven Differentially Expressed Genes. Xu HH; Wang HL; Xing TJ; Wang XQ Front Immunol; 2022; 13():851622. PubMed ID: 35924232 [TBL] [Abstract][Full Text] [Related]
13. Unraveling the role of the circadian clock genes in cervical squamous cell carcinoma and endocervical adenocarcinoma: A prognostic indicator for prognostic, immunotherapy response, and chemotherapy sensitivity. Xu J; Huang X; Gou S; Luo H; Zeng S; Zhang Q; Wu Q; Chi H; Yang G J Cancer; 2024; 15(9):2788-2804. PubMed ID: 38577592 [No Abstract] [Full Text] [Related]
14. Elucidating prognosis in cervical squamous cell carcinoma and endocervical adenocarcinoma: a novel anoikis-related gene signature model. Wang M; Ying Q; Ding R; Xing Y; Wang J; Pan Y; Pan B; Xiang G; Liu Z Front Oncol; 2024; 14():1352638. PubMed ID: 38988712 [TBL] [Abstract][Full Text] [Related]
15. Ferroptosis-related genes identify tumor immune microenvironment characterization for the prediction of prognosis in cervical cancer. Yang X; Yin F; Liu Q; Ma Y; Zhang H; Guo P; Wen W; Guo X; Wu Y; Yang Z; Han Y Ann Transl Med; 2022 Jan; 10(2):123. PubMed ID: 35282071 [TBL] [Abstract][Full Text] [Related]
16. Exploring Potential Regulatory Anesthetic Drugs Based on RNA Binding Protein and Constructing CESC Prognosis Model: A Study Based on TCGA Database. Zheng Y; Meng XW; Yang JP Front Surg; 2022; 9():823566. PubMed ID: 35449547 [TBL] [Abstract][Full Text] [Related]
17. A Comprehensive RNA Expression Signature for Cervical Squamous Cell Carcinoma Prognosis. Xiong J; Guo S; Bing Z; Su Y; Guo L Front Genet; 2018; 9():696. PubMed ID: 30662454 [TBL] [Abstract][Full Text] [Related]
18. Exploration of potential therapeutic and prognostic value of CXC chemokines in cervical squamous cell carcinoma and endocervical adenocarcinoma based on bioinformatics analysis. Wu C; Ma C; Yuan J; Zhou P Math Biosci Eng; 2021 Sep; 18(6):8201-8222. PubMed ID: 34814296 [TBL] [Abstract][Full Text] [Related]
19. Comprehensive Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B Front Immunol; 2022; 13():931906. PubMed ID: 35958598 [TBL] [Abstract][Full Text] [Related]
20. Prognostic Signatures Based on Ferroptosis- and Immune-Related Genes for Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma. Xing C; Yin H; Yao ZY; Xing XL Front Oncol; 2021; 11():774558. PubMed ID: 35087751 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]